Thomas E. Boyd

3.8k total citations · 1 hit paper
56 papers, 2.4k citations indexed

About

Thomas E. Boyd is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Thomas E. Boyd has authored 56 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 22 papers in Pathology and Forensic Medicine and 19 papers in Oncology. Recurrent topics in Thomas E. Boyd's work include Chronic Lymphocytic Leukemia Research (34 papers), Lymphoma Diagnosis and Treatment (22 papers) and Immunodeficiency and Autoimmune Disorders (10 papers). Thomas E. Boyd is often cited by papers focused on Chronic Lymphocytic Leukemia Research (34 papers), Lymphoma Diagnosis and Treatment (22 papers) and Immunodeficiency and Autoimmune Disorders (10 papers). Thomas E. Boyd collaborates with scholars based in United States, France and United Kingdom. Thomas E. Boyd's co-authors include Nathan Fowler, Jeff P. Sharman, Richard R. Furman, Kathryn S. Kolibaba, Ranjana H. Advani, Sonali M. Smith, Ahmed Hamdy, Joseph J. Buggy, Barbara Grant and Betty Chang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Thomas E. Boyd

55 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

2012 848 citations Ranjana H. Advani, Joseph J. Buggy et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas E. Boyd United States	22	1.4k	1.2k	751	727	555	56	2.4k
Ellen Schlette United States	28	1.3k 1.0×	1.3k 1.1×	701 0.9×	700 1.0×	632 1.1×	69	2.3k
Stephen E. Spurgeon United States	25	1.6k 1.1×	1.3k 1.1×	794 1.1×	690 0.9×	549 1.0×	98	2.4k
Soham D. Puvvada United States	17	1.1k 0.8×	990 0.8×	810 1.1×	1.0k 1.4×	415 0.7×	59	2.6k
Sarah E. M. Herman United States	19	2.1k 1.5×	1.6k 1.4×	514 0.7×	504 0.7×	1.0k 1.8×	42	2.5k
Marta Crespo Spain	19	1.5k 1.1×	1.3k 1.1×	870 1.2×	619 0.9×	925 1.7×	52	2.7k
Monica Else United Kingdom	22	1.6k 1.1×	1.2k 1.0×	428 0.6×	403 0.6×	712 1.3×	42	2.0k
Ilaria Del Giudice Italy	24	1.5k 1.1×	1.3k 1.1×	331 0.4×	408 0.6×	764 1.4×	82	1.9k
Wojciech Jurczak Poland	22	1.6k 1.1×	2.3k 1.9×	496 0.7×	1.5k 2.1×	717 1.3×	281	3.4k
Paul M. Barr United States	32	2.5k 1.8×	2.6k 2.2×	642 0.9×	1.2k 1.6×	951 1.7×	188	3.9k
Jacqueline C. Barrientos United States	27	2.3k 1.6×	1.9k 1.6×	543 0.7×	630 0.9×	995 1.8×	178	2.9k

Countries citing papers authored by Thomas E. Boyd

Since Specialization

Citations

This map shows the geographic impact of Thomas E. Boyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Boyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Boyd more than expected).

Fields of papers citing papers by Thomas E. Boyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Boyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Boyd. The network helps show where Thomas E. Boyd may publish in the future.

Co-authorship network of co-authors of Thomas E. Boyd

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Boyd. A scholar is included among the top collaborators of Thomas E. Boyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Boyd. Thomas E. Boyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stewart, Tracy Murray, Daniel D. Von Hoff, Michael L. Fitzgerald, et al.. (2020). A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Cancer Chemotherapy and Pharmacology. 87(1). 135–144. 15 indexed citations

Phillips, Tycel, Paul M. Barr, Steven I. Park, et al.. (2018). A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Investigational New Drugs. 37(2). 297–306. 57 indexed citations

Garcia‐Manero, Guillermo, Bart L. Scott, Christopher R. Cogle, et al.. (2018). CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leukemia Research. 72. 79–85. 15 indexed citations

Albany, Costantine, Lawrence H. Einhorn, Lawrence Garbo, et al.. (2017). Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. The Oncologist. 23(3). 316–323. 40 indexed citations

Scagliotti, Giorgio V., Jin Hyoung Kang, David C. Smith, et al.. (2016). Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Investigational New Drugs. 34(5). 625–635. 55 indexed citations

Garcia‐Manero, Guillermo, Michael R. Savona, Steven D. Gore, et al.. (2016). CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies. Blood. 128(22). 905–905. 5 indexed citations

Cheng, Heather H., Colin C. Pritchard, Thomas E. Boyd, Peter S. Nelson, & Bruce Montgomery. (2015). Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. European Urology. 69(6). 992–995. 188 indexed citations

Komrokji, Rami S., G. García-Manero, Lionel Adès, et al.. (2015). 14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION. Leukemia Research. 39. S5–S6. 9 indexed citations

Sharman, Jeff P., Andrei R. Shustov, Mitchell R. Smith, et al.. (2015). Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling. Blood. 126(23). 1744–1744. 3 indexed citations

10.

Smith, David A., Paul Conkling, Donald Richards, et al.. (2014). Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. Cancer Immunology Immunotherapy. 63(8). 787–796. 58 indexed citations

11.

Komrokji, Rami S., Guillermo Garcia‐Manero, Lionel Adès, et al.. (2014). An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. Blood. 124(21). 3251–3251. 20 indexed citations

12.

Vos, Sven de, Nina D. Wagner‐Johnston, Steven Coutré, et al.. (2014). Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results. Blood. 124(21). 3063–3063. 10 indexed citations

13.

Hillmen, Peter, Tadeusz Robak, Ann Janssens, et al.. (2013). Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). Blood. 122(21). 528–528. 58 indexed citations

14.

Laille, Eric, Michael R. Savona, Bart L. Scott, et al.. (2013). Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. The Journal of Clinical Pharmacology. 54(6). 630–639. 26 indexed citations

15.

Vos, Sven de, Richard R. Furman, Jacqueline C. Barrientos, et al.. (2013). Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood. 122(21). 2878–2878. 18 indexed citations

16.

Advani, Ranjana H., Joseph J. Buggy, Jeff P. Sharman, et al.. (2012). Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. Journal of Clinical Oncology. 31(1). 88–94. 848 indexed citations breakdown →

17.

Sharman, Jeff P., Jerome H. Goldschmidt, John M. Burke, et al.. (2012). CD30 expression in nonlymphomatous malignancies.. Journal of Clinical Oncology. 30(15_suppl). 3069–3069. 10 indexed citations

18.

Fowler, Nathan, Sonali M. Smith, Thomas E. Boyd, et al.. (2010). The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study. Blood. 116(21). 964–964. 36 indexed citations

19.

Pollyea, Daniel A., Sonali M. Smith, Nathan Fowler, et al.. (2009). A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay.. Blood. 114(22). 3713–3713. 8 indexed citations

20.

Herbst, Roy S., Rafat Ansari, В. А. Горбунова, et al.. (2007). B1-06: Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S335–S335. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact